Addictive Disorders in Cardiovascular Medicine

Zusammenfassung Hintergrund: Im Jahr 2014 wurde das DSM-IV durch die fünfte Version des Diagnostischen und Statistischen Manuals Psychischer Störungen (DSM-5) abgelöst. In der vorliegenden Übersicht soll auf die Darstellung der Abhängigkeitserkrankungen im DSM-5 (Kapitel: Substance Related and Addictive Disorders, in der Übersetzung: Störungen im Zusammenhang mit psychotropen Substanzen und abhängige Verhaltensweisen) eingegangen werden. Ziel: Nach einem Überblick über die neue Systematik werden die entsprechenden Änderungen und Besonderheiten gegenüber DSM-IV und ICD-10 erläutert, sowie die Rezeption im deutschsprachigen Raum dargestellt.

Download Full-text

Exploring the Frontiers of Regenerative Cardiovascular Medicine

10.3389/978-2-88945-818-9 ◽

2019 ◽

Keyword(s):

Cardiovascular Medicine

Download Full-text

Breakthrough Regenerative Cardiopoietic Stem Cells and Related Technologies in the Field of Cardiovascular Medicine – From Bench to Bedside

Interventional Cardiology Review ◽

10.15420/icr.2012.7.1.14 ◽

2012 ◽

Vol 7 (1) ◽

pp. 14

Author(s):

Christian Homsy ◽

Keyword(s):

Stem Cells ◽

Cell Therapy ◽

Progenitor Cells ◽

Cardiac Disease ◽

Cardiac Tissue ◽

Cardiac Repair ◽

Cardiac Diseases ◽

Cardiac Progenitor Cells ◽

Biotechnology Company ◽

Cardiovascular Medicine

The scale of cardiac diseases, and in particular heart failure and acute myocardial infarction, emphasises the need for radically new approaches, such as cell therapy, to address the underlying cause of the disease, the loss of functional myocardium. Stem cell-based therapies, whether through transplanted cells or directing innate repair, may provide regenerative approaches to cardiac diseases by halting, or even reversing, the events responsible for progression of organ failure. Cardio3 BioSciences, a leading Belgian biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac disease, was founded in this context in 2004. The company is developing a highly innovative cell therapy approach based on a platform designed to reprogramme the patient’s own stem cells into cardiac progenitor cells. The underlying rationale behind this approach is that, in order to reconstruct cardiac tissue, stem cells need to be specific to cardiac tissue. The key is therefore to provide cardiac-specific progenitor cells to the failing heart to induce cardiac repair.

Download Full-text